CR20220520A - Inhibidor de ret cristalino - Google Patents

Inhibidor de ret cristalino

Info

Publication number
CR20220520A
CR20220520A CR20220520A CR20220520A CR20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A CR 20220520 A CR20220520 A CR 20220520A
Authority
CR
Costa Rica
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
CR20220520A
Other languages
English (en)
Inventor
Jeremy Miles Merritt
Jon Gordon Selbo
Mark Steven Kerr
Douglas Patton Kjell
Shekhar Krishna Viswanath
Rajni Miglani Bhardwaj
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of CR20220520A publication Critical patent/CR20220520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.
CR20220520A 2020-04-17 2021-04-09 Inhibidor de ret cristalino CR20220520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
CR20220520A true CR20220520A (es) 2022-11-15

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220520A CR20220520A (es) 2020-04-17 2021-04-09 Inhibidor de ret cristalino

Country Status (17)

Country Link
EP (1) EP4136090A1 (es)
JP (1) JP2023522012A (es)
KR (1) KR20230002706A (es)
CN (1) CN115916791A (es)
AU (1) AU2021255488A1 (es)
BR (1) BR112022020446A2 (es)
CA (1) CA3174316A1 (es)
CL (1) CL2022002849A1 (es)
CO (1) CO2022014882A2 (es)
CR (1) CR20220520A (es)
DO (1) DOP2022000221A (es)
EC (1) ECSP22080982A (es)
IL (1) IL297212A (es)
MX (1) MX2022012952A (es)
PE (1) PE20230388A1 (es)
TW (1) TW202202501A (es)
WO (1) WO2021211380A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
US20230183266A1 (en) 2021-12-13 2023-06-15 Loxo Oncology, Inc. Crystalline forms of ret inhibitor and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. SUBSTITUTED PYRAZOLE-CONDENSED RING DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
TW202202501A (zh) 2022-01-16
BR112022020446A2 (pt) 2022-11-29
CN115916791A (zh) 2023-04-04
CO2022014882A2 (es) 2022-10-31
DOP2022000221A (es) 2023-01-15
MX2022012952A (es) 2023-01-11
EP4136090A1 (en) 2023-02-22
JP2023522012A (ja) 2023-05-26
ECSP22080982A (es) 2023-01-31
CA3174316A1 (en) 2021-10-21
PE20230388A1 (es) 2023-03-06
KR20230002706A (ko) 2023-01-05
CL2022002849A1 (es) 2023-06-16
IL297212A (en) 2022-12-01
WO2021211380A1 (en) 2021-10-21
AU2021255488A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
MX2022012952A (es) Inhibidor de ret cristalino.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
IL287032A (en) Preparations and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with disease-causing microorganisms
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2022000845A (es) Compuestos inhibidores.
MX2021011488A (es) Compuestos y usos de estos.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2020009942A (es) Compuestos y usos de los mismos.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2021008903A (es) Compuestos y usos de los mismos.
AU2018322386C1 (en) Kinase mutation-associated neurodegenerative disorders
WO2022216379A8 (en) Combination therapies for the treatment of cancer
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2021003992A (es) Inhibidores de la acido graso sintasa (fasn).
MX2022001274A (es) Agente serotoninergico y antagonista del receptor 5-ht1a.